The AcQMap system has been developed to identify and show both standard voltage-based and higher resolution charge-source (dipole density) maps.

It is capable of generating real-time, 3D images of the heart chamber using ultrasound, which can be compared to a CT or MRI.

According to the company, dipole non-contact mapping creates an accurate and instantaneous global view that captures the activation pattern of every heartbeat, making it capable of mapping and displaying both stable and unstable cardiac arrhythmias.

The AcQMap system is not yet approved for sale in the US.

Acutus Medical president and CEO Randy Werneth said: "The CE Mark approval of our AcQMap System marks a significant milestone for the company and for the EP community.

"AcQMap will provide for the first time, the ability to unlock the mysteries of cardiac activation by truly mapping complex arrhythmias in real-time, enabling clear identification of mechanisms, and providing an accurate guide for ablation therapy."

The company is showcasing the AcQMap system at the Heart Rhythm Society Meeting in San Francisco, which is being held from 4 to 7 May.

Image: Image produced by the AcQMap high resolution imaging and mapping system. Photo: courtesy of Business Wire.